– Reuters Citing Sources
Dicerna Pharmaceuticals Q3 EPS $(0.22) Beats $(0.46) Estimate, Sales $62.95M Beat $43.78M Estimate
Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.46) by 52.17 percent. This is a 24.14 percent increase over losses of $(0.29) per